ARTICLE | Clinical News
Matrix Pharma preclinical data
November 22, 1999 8:00 AM UTC
MATX presented data showing that the combination of FMdC and cisplatin gave up to 2 times the anti-tumor activity in mouse models of non-small cell lung cancer than would be expected from the additive effects of the two compounds alone. The timing of administration of the two agents also affected efficacy. Data were presented at the Molecular Targets and Cancer Therapeutics conference in Washington. ...